Fierce Pharma

MARCH 22, 2024

Sales are booming for Novo Nordisk’s GLP-1 treatments for diabetes and obesity. But that doesn’t mean the Danish company has moved on from its previous generation of blood sugar modulators. | With a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), Novo has come a step closer to bringing its revolutionary Awiqli (once weekly basal insulin icodec) to the market.

Medicine 320

Medicine Sales Marketing 320

MedCity News

MARCH 22, 2024

A CPO in the C-suite determines how a health system can move from a cost center to a revenue center with healthy operating margins by investing in specialty pharmacy services that reduce burden for healthcare staff and improve care for patients.

Healthcare 117

Healthcare Healthcare Patients 117

Fierce Pharma

MARCH 22, 2024

At a watershed moment for Duchenne muscular dystrophy (DMD) treatment, privately held Italian drugmaker Italfarmaco has added a new therapeutic option to the armamentarium against the debilitating | At a watershed moment for Duchenne muscular dystrophy treatment, privately held Italian drugmaker Italfarmaco has added a new therapeutic option to the armamentarium against the debilitating muscle-wasting disorder.

FDA 296

FDA 296

MedCity News

MARCH 22, 2024

Corticosteroids are a standard first-line treatment for Duchenne muscular dystrophy, but these drugs have many side effects. FDA approval of Italfarmaco’s Duvyzat is the first nonsteroidal drug to pass the agency’s regulatory bar for treating this rare disease.

Side effects 117

Side effects FDA Patients Biopharma 117

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Fierce Pharma

MARCH 22, 2024

At a time of heightened geopolitical tensions between the U.S. and China, Eli Lilly’s CEO said the Indianapolis-based company remains committed to the Chinese market. | David Ricks’ visit to China comes as Lilly has several key drug applications under review at local regulators.

Marketing 283

Marketing 283

MedCity News

MARCH 22, 2024

Today, new digital solutions are emerging that provide tailored exercise programs and encourage small changes to daily life that can lead to significantly lower fall risk.

Leads 117

Leads 117

MedCity News

MARCH 22, 2024

Collaboration across key stakeholders, including home health agencies, providers, patients, health plans, and post-acute care solution providers will be critical to fully enabling the home as a preferred place of care.

Patients 114

Patients Healthcare Healthcare 114

Pharmaceutical Commerce

MARCH 22, 2024

In an interview with Pharma Commerce Associate Editor Don Tracy, Amy Niles, Chief Mission Officer, The PAN Foundation discusses the overall mission of the organization.

Pharma 105

Pharma 105

MedCity News

MARCH 22, 2024

During a panel at HIMSS, three health system leaders explained what digital transformation means to them and how they’re seeking it play out at their organizations.

Medical 113

Medical Healthcare Healthcare 113

pharmaphorum

MARCH 22, 2024

Medicare has loosened restrictions on the reimbursement of obesity drugs, thanks to clinical data showing they can improve cardiovascular outcomes, but their price could be up for negotiation.

99

99

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

MARCH 22, 2024

Humana and DUOS have partnered to launch a new program that supports Humana’s Louisiana veteran seniors with a chronic condition. These veterans will be connected to DUOS, which can address their health-related social needs.

107

107

PM360

MARCH 22, 2024

It is with immense sadness that I write this. A one of a kind, loyal, and generous friend and mentor. I will miss his humor, unrivaled intelligence, guidance, wisdom—and I can’t leave out his fashion sense, especially those killer shoes. Rest in peace my very dear friend.

98

98

pharmaphorum

MARCH 22, 2024

First report from PHTI concludes that digital health technologies for diabetes management deliver minimal clinical benefit and raise healthcare costs

Healthcare 107

Healthcare Healthcare Management 107

Pharmaceutical Technology

MARCH 22, 2024

The EMA CHMP has recommended marketing authorisation for Novo Nordisk's Awiqli for treating diabetes in adult patients.

Marketing 105

Marketing Patients 105

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

pharmaphorum

MARCH 22, 2024

Italfarmaco’s non-steroidal drug Duvyzat (givinostat) has been approved in the US as a treatment for Duchenne muscular dystrophy (DMD)

FDA 100

FDA 100

Pharmaceutical Technology

MARCH 22, 2024

The US FDA has granted ODD to HI-Bio's felzartamab to treat antibody-mediated rejection (AMR) in kidney transplant recipients.

FDA 97

FDA 97

pharmaphorum

MARCH 22, 2024

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

FDA 83

FDA Pharmaceutical 83

European Pharmaceutical Review

MARCH 22, 2024

Research suggests that combining ribociclib with hormone therapy improved invasive-free survival in stage 2 or 3 HR-positive, HER2-negative early breast cancer. The study data showed that distant disease-free survival and recurrence-free survival improved when the small molecule CDK4/6 inhibitor ribociclib was used alongside a nonsteroidal aromatase inhibitor (NSAI).

Medicine 81

Medicine Patients Pharmaceutical 81

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

pharmaphorum

MARCH 22, 2024

It has been a bumper week for biotech financings, with a $400m Series A for Mirador heading, topping impressive rounds for Capstan, Clasp, Engrail, Enliven, and Nouscom.

82

82

PharmaTimes

MARCH 22, 2024

Dementia is estimated to affect 850,000 people in the UK and costs the nation around £23bn a year

95

95

PharmaVoice

MARCH 22, 2024

After getting her start as a nurse, Debra Weiss worked her way up the corporate ladder and is now COO of Gates MRI, which just launched its first phase 3 trial for tuberculosis.

Leads 52

Leads Pharma 52

PharmaTimes

MARCH 22, 2024

These types of conditions are responsible for 25% of all UK deaths and affect 7.

95

95

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management

Clarify Health

MARCH 22, 2024

While healthcare price transparency regulations aim to empower patients and promote competition in the market, providers face significant challenges in implementing and complying with these requirements effectively. Implementing price transparency requires a robust technology infrastructure to collect, store, update, and disseminate pricing information effectively.

Healthcare Provider 52

Healthcare Provider Healthcare Healthcare Competition 52

PM360

MARCH 22, 2024

The effective ongoing incorporation of Artificial Intelligence (AI) has emerged as a pivotal force within the pharmaceutical sector, reshaping the traditional paradigms of drug discovery, development, and commercialization. However, it’s also charting new waters for consultancies supporting the sector. How do AI and strategy consultants fit together?

Consulting 52

Consulting Training Recruitment Physicians 52

PharmExec

MARCH 22, 2024

In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses the three drugs featured in their Drug Pipeline Insights Report for 2024 and which unmet needs they address.

Pharmaceutical 52

Pharmaceutical 52

PM360

MARCH 22, 2024

Exploring the role of patient advocacy groups and clinical trials while discussing the challenges faced, and how artificial intelligence and modern methods revolutionize the landscape. Despite the unique traits exhibited by approximately 11,000 rare diseases (RD), patients commonly face challenges due to the diseases’ low prevalence, including feelings of isolation and navigating overwhelming information about their condition 1.

Patients 52

Patients Recruitment Ethics Government 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Pharmaceutical Technology

MARCH 22, 2024

Discover how Vanda Pharmaceuticals' patent for R-P88 offers a groundbreaking treatment for psychiatric disorders, simplifying dosing and administration for patients and healthcare providers.

Pharmaceutical 52

Pharmaceutical Healthcare Provider Healthcare Healthcare 52

PM360

MARCH 22, 2024

DISCOVERIES & INNOVATION CAR T Cells May Be the Answer to a Longer Life CAR (chimeric antigen receptor) T cells just might be the secret weapon against aging. Cold Spring Harbor Laboratory (CSHL) Assistant Professor Corina Amor Vegas and colleagues have discovered that T cells are white blood cells that can attack another group known as senescent cells.

Food and Drug Administration 52

Food and Drug Administration FDA Healthcare Healthcare 52

PharmExec

MARCH 22, 2024

Duvyzat (givinostat) is histone deacetylase inhibitor that was previously granted priority review, orphan drug designation, and rare pediatric disease designation by the FDA for patients 6 years of age and older with Duchenne muscular dystrophy.

FDA 52

FDA Patients 52

PM360

MARCH 22, 2024

Field Medical Affairs exists as a trusted relationship-builder within the medical industry and turns to advance science to help the discussions between MSLs and HCPs on treatment possibilites and scientific concerns. Field Medical Affairs is an essential bridge between pharmaceutical clinical development and commercial delivery. Without the imperative of immediate commercial outcomes, Field Medical Affairs also exists as a trusted relationship-builder in which medical science liaisons (MSLs) and

Medical 52

Medical Education Medical science Sales 52

Advertisement

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.

Patients